Aldeyra (ALDX)

What Moves the Stock

1. 01Phase 3 clinical trial topline data releases for reproxalap in dry eye disease and allergic conjunctivitis (primary endpoints: sign/symptom scores)
2. 02FDA regulatory interactions: End-of-Phase 2 meeting feedback, NDA submission timing, Advisory Committee outcomes, approval decisions
3. 03Cash position and financing events: equity offerings (dilutive but extend runway), partnership announcements with upfront payments/milestones
4. 04Competitive landscape shifts: approval or failure of competing dry eye therapies, new mechanism entrants, patent challenges
5. 05Pipeline expansion: IND filings for systemic RASP inhibitors, proof-of-concept data in autoimmune indications beyond ophthalmology
6. 06No current revenue - pre-commercialization stage
7. 07Future potential: Reproxalap ophthalmic solution for dry eye disease (estimated $4B+ US market)
8. 08Future potential: Reproxalap for allergic conjunctivitis and systemic autoimmune indications

ALDX Chart

My Notes

• growth/speculative - Aldeyra attracts biotech specialists, event-driven hedge funds…
• Rising interest rates negatively impact Aldeyra through two channels: (1) Valuation compression - clinical-stage biotechs are long-duration…
• Watch on earnings: Reproxalap Phase 3 trial enrollment progress and topline data announcement dates (primary catalyst), Quarterly cash burn rate and ending cash balance (runway calculation: cash ÷ quarterly burn), FDA correspondence and regulatory milestone achievements (IND clearances, meeting minutes, NDA acceptance).